2-(2,6-Dimethylpyridin-4-yl)-4-methyl-8-pyridin-3-ylpyrazolo[1,5-a]quinazolin-5-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 2-(2,6-Dimethylpyridin-4-yl)-4-methyl-8-pyridin-3-ylpyrazolo[1,5-a]quinazolin-5-one
• 英文别名: 2-(2,6-dimethylpyridin-4-yl)-4-methyl-8-pyridin-3-ylpyrazolo[1,5-a]quinazolin-5-one
• 化学式: C₂₃H₁₉N₅O
• 分子量: 381.4
• InChiKey: MAXVIIYLTAXDBA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  29
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  63.9
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• [EN] SUBSTITUTED PYRAZOLOQUINAZOLINONES AND PYRROLOQUINAZOLINONES AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS<br/>[FR] PYRAZOLOQUINAZOLINONES ET PYRROLOQUINAZOLINONES SUBSTITUÉES COMME MODULATEURS ALLOSTÉRIQUES DES RÉCEPTEURS MÉTABOTROPIQUES DU GLUTAMATE DE GROUPE II
  申请人：DOMAIN THERAPEUTICS

  公开号：WO2013174822A1

  公开（公告）日：2013-11-28

  The present invention relates to the pyrazoloquinazolinone and pyrroloquinazolinone derivatives of the general formula (I), as well as pharmaceutical compositions containing them, and their use in the treatment and/or prophylaxis of conditions associated with altered glutamatergic signalling and/or functions, and/or conditions which can be affected by alteration of glutamate level or signalling in mammals, in particular their use in the treatment and/or prophylaxis of acute and chronic neurological and/or psychiatric disorders.

  本发明涉及一般式（I）的吡唑喹唑啉酮和吡咯喹唑啉酮衍生物，以及含有它们的药物组合物，以及它们在治疗和/或预防与改变谷氨酸能信号和/或功能相关的疾病以及/或在哺乳动物中可以受到谷氨酸水平或信号改变影响的疾病，特别是在治疗和/或预防急性和慢性神经和/或精神障碍中的应用。
• SUBSTITUTED PYRAZOLOQUINAZOLINONES AND PYRROLOQUINAZOLINONES AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS
  申请人：Domain Therapeutics

  公开号：US20150105381A1

  公开（公告）日：2015-04-16

  The present invention relates to the pyrazoloquinazolinone and pyrroloquinazolinone derivatives of the general formula (I), as well as pharmaceutical compositions containing them, and their use in the treatment and/or prophylaxis of conditions associated with altered glutamatergic signalling and/or functions, and/or conditions which can be affected by alteration of glutamate level or signalling in mammals, in particular their use in the treatment and/or prophylaxis of acute and chronic neurological and/or psychiatric disorders.

  本发明涉及一般式(I)的吡唑喹唑酮和吡咯喹唑酮衍生物，以及包含它们的制药组合物，以及它们在治疗和/或预防与改变谷氨酸能信号和/或功能相关的疾病和/或在哺乳动物中可以受到谷氨酸水平或信号改变影响的疾病中的应用，特别是在治疗和/或预防急性和慢性神经和/或精神障碍方面的应用。
• Neoepitope Detection of Disease Using Protein Arrays
  申请人：Tainsky Michael

  公开号：US20080300141A1

  公开（公告）日：2008-12-04

  A biosensor for use in detecting the presence of diseases, the biosensor comprising a detector for detecting a presence of at least one marker indicative of a specific disease. A method of determining efficacy of a pharmaceutical for treating a disease or staging disease by administering a pharmaceutical to a sample containing markers for a disease, detecting the amount of at least one marker of the disease in the sample, and analyzing the amount of the marker in the sample, whereby the amount of marker correlates to pharmaceutical efficacy or disease stage. Markers for gynecological disease selected from the list in Table 8. An immuno-imaging agent comprising labeled antibodies, whereby the labeled antibodies are isolated and reactive to proteins overexpressed in vivo. Informatics software for analyzing the arrays of claim 17 , the software including analyzing means for analyzing the arrays.
• US9434734B2
  申请人：——

  公开号：US9434734B2

  公开（公告）日：2016-09-06